Keywords: AE; adverse event; CDSR; Cochrane Database of Systematic Reviews; COMTI; catechol-O-methyltransferase inhibitor; DOPA; dopamine; FDA; Food and Drug Administration; GABA; γ-aminobutyric acid; GnRH; gonadotropin-releasing hormone; IQR; interquartile range;